The FDA has approved a new drug called Ziextenzo (pegfilgrastim-bmez). It is a biosimilar, which means it is highly similar to an already approved drug (Neulasta) and works the same way. Ziextenzo is a leukocyte growth factor that helps the body make more white blood cells. This can lower the chance of serious infections in people with certain cancers who are getting chemotherapy. It is also approved to help people who have been exposed to high levels of radiation.
Ziextenzo is for patients with non-myeloid malignancies (cancers that do not start in the bone marrow) who are receiving chemotherapy that can cause a drop in white blood cells. The drug is given as a single injection under the skin, usually 6 mg, once per chemotherapy cycle. It should be given at least 24 hours after chemotherapy and no less than 14 days before the next cycle.
This approval gives doctors and patients another option for managing the side effects of chemotherapy. It is important to know that Ziextenzo is not used to collect stem cells for transplant. If you are getting chemotherapy, talk to your doctor about whether this drug is right for you. Your doctor can help you understand the risks and benefits based on your specific treatment plan.